Results 21 to 30 of about 26,895 (263)
Neuroprotective Effect of SGLT2 Inhibitors [PDF]
Molecules, 2021 Patients with diabetes are at higher risk of cardiovascular diseases and cognitive impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Sotagliflozin) are newer hypoglycemic agents with many pleiotropic effects. In this review, we discuss their neuroprotective potential.
Agnieszka Pawlos +3 more
openaire +3 more sources
SGLT2 Inhibitors: Physiology and Pharmacology [PDF]
Kidney360, 2021 SGLTs are sodium glucose transporters found on the luminal membrane of the proximal tubule, where they reabsorb some 180 g (1 mol) of glucose from the glomerular filtrate each day. The natural glucoside phlorizin completely blocks glucose reabsorption. Oral SGLT2 inhibitors are rapidly absorbed into the blood stream, where theyremain in the circulation
openaire +2 more sources
Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis.
PLoS ONE, 2022 IntroductionSodium-glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of antidiabetic drugs. Emerging findings from laboratory studies indicate that SGLT2 inhibitors can improve liver function and suppress the proliferation of ...
Michael Hendryx +3 more
doaj +1 more source
Cell Death and Disease, 2022 SGLT2 (sodium-glucose cotransporter 2) is an important mediator of epithelial glucose transport and has been reported that SGLT2, robustly and diffusely expressed in malignant cancer cells, was overexpressed in various tumors, and inhibiting the SGLT2 ...
Wei Wu +6 more
doaj +1 more source
Diabetic ketoacidosis with SGLT2 inhibitors [PDF]
BMJ, 2020 ### What you need to know A 45 year old woman with type 2 diabetes complains of malaise, shortness of breath, and nausea for two days. She has been taking metformin and insulin. She was started on canagliflozin six weeks earlier to improve glycaemic control. Over the previous week she has halved the insulin dose. On examination, she is drowsy.
Giovanni, Musso +3 more
openaire +2 more sources
Development of SGLT1 and SGLT2 inhibitors [PDF]
Diabetologia, 2018 Sodium-glucose cotransporters SGLT1 (encoded by SGLT1, also known as SLC5A1) and SGLT2 (encoded by SGLT2, also known as SLC5A2) are important mediators of epithelial glucose transport. While SGLT1 accounts for most of the dietary glucose uptake in the intestine, SGLT2 is responsible for the majority of glucose reuptake in the tubular system of the ...
Timo Rieg, Volker Vallon
openaire +4 more sources
Journal of Diabetes Investigation, 2022 Aims/Introduction We evaluated the effect of co‐administration of esaxerenone and a sodium–glucose cotransporter 2 (SGLT2) inhibitor on the magnitude of serum potassium elevation in Japanese patients with diabetic kidney disease. Materials and Methods We
Kenichi Shikata +7 more
doaj +1 more source
Possible renoprotective mechanisms of SGLT2 inhibitors
Frontiers in Medicine, 2023 Treatment with a sodium glucose cotransporter 2 (SGLT2) inhibitor in patients with chronic kidney disease reduces the renal risk independent of changes in blood glucose concentrations and blood pressure.
Akira Nishiyama, Kento Kitada
doaj +1 more source
SGLT2 Inhibitors and the Diabetic Kidney [PDF]
Diabetes Care, 2016 Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium–glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may ...
FIORETTO, PAOLA +4 more
openaire +3 more sources
Medicines, 2022 Background: The incidence and risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM) who use sodium glucose co-transporter-2 (SGLT2) inhibitors are still controversial.
Suriyon Uitrakul +4 more
doaj +1 more source